JOP20200253A1 - تركيبات وطرق لعلاج الحثل البقعي - Google Patents
تركيبات وطرق لعلاج الحثل البقعيInfo
- Publication number
- JOP20200253A1 JOP20200253A1 JOP/2020/0253A JOP20200253A JOP20200253A1 JO P20200253 A1 JOP20200253 A1 JO P20200253A1 JO P20200253 A JOP20200253 A JO P20200253A JO P20200253 A1 JOP20200253 A1 JO P20200253A1
- Authority
- JO
- Jordan
- Prior art keywords
- macular dystrophy
- compositions
- methods
- treating macular
- sequence encoding
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000035719 Maculopathy Diseases 0.000 title abstract 2
- 208000002780 macular degeneration Diseases 0.000 title abstract 2
- 102000012304 Bestrophin Human genes 0.000 abstract 2
- 108050002823 Bestrophin Proteins 0.000 abstract 2
- 102100022794 Bestrophin-1 Human genes 0.000 abstract 2
- 108050003623 Bestrophin-1 Proteins 0.000 abstract 2
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 abstract 2
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Manufacturing & Machinery (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862653131P | 2018-04-05 | 2018-04-05 | |
| PCT/US2019/026062 WO2019195727A1 (en) | 2018-04-05 | 2019-04-05 | Compositions and methods for treating macular dystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20200253A1 true JOP20200253A1 (ar) | 2020-10-04 |
Family
ID=66223872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2020/0253A JOP20200253A1 (ar) | 2018-04-05 | 2019-04-05 | تركيبات وطرق لعلاج الحثل البقعي |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20190307900A1 (enExample) |
| EP (1) | EP3775233A1 (enExample) |
| JP (1) | JP2021520232A (enExample) |
| KR (1) | KR20210005040A (enExample) |
| CN (1) | CN113056561A (enExample) |
| AU (1) | AU2019247864A1 (enExample) |
| BR (1) | BR112020020204A2 (enExample) |
| CA (1) | CA3096088A1 (enExample) |
| CL (1) | CL2020002561A1 (enExample) |
| CO (1) | CO2020013690A2 (enExample) |
| EA (1) | EA202092069A1 (enExample) |
| IL (1) | IL277779A (enExample) |
| JO (1) | JOP20200253A1 (enExample) |
| MA (1) | MA52199A (enExample) |
| MX (1) | MX2020010477A (enExample) |
| PE (1) | PE20210918A1 (enExample) |
| PH (1) | PH12020551641A1 (enExample) |
| RU (1) | RU2020132890A (enExample) |
| SG (1) | SG11202009759SA (enExample) |
| TW (1) | TW202003052A (enExample) |
| WO (1) | WO2019195727A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020047476A1 (en) * | 2018-08-31 | 2020-03-05 | University Of Florida Research Foundation, Incorporated | Adeno-associated viral vectors for the treatment of best disease |
| EP3870148A4 (en) | 2018-10-25 | 2022-11-09 | Takeda Pharmaceutical Company Limited | AAV TRIPLE PLASMID SYSTEM |
| WO2020140007A1 (en) * | 2018-12-28 | 2020-07-02 | University Of Rochester | Gene therapy for best1 dominant mutations |
| BR112022017182A2 (pt) * | 2020-02-28 | 2022-11-08 | Univ Pennsylvania | Tratamento de bestrofinopatias autossômicas recessivas e métodos para avaliação das mesmas |
| CN111849998A (zh) * | 2020-07-29 | 2020-10-30 | 武汉纽福斯生物科技有限公司 | 编码人卵黄状黄斑病蛋白1的核酸分子及其应用 |
| WO2024064608A2 (en) * | 2022-09-20 | 2024-03-28 | Intergalactic Therapeutics, Inc. | Best1 vectors and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009153563A1 (en) * | 2008-06-18 | 2009-12-23 | Oxford Biomedica (Uk) Limited | Virus purification |
| US9163259B2 (en) * | 2012-05-04 | 2015-10-20 | Novartis Ag | Viral vectors for the treatment of retinal dystrophy |
| CA2930282C (en) * | 2013-11-20 | 2024-09-10 | Universita Degli Studi Di Napoli Federico Ii | Artificial DNA-Binding Proteins and Their Uses |
| KR102281881B1 (ko) * | 2013-12-06 | 2021-07-27 | 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) | 대상체의 망막 색소 상피에서 목적 폴리뉴클레오티드를 발현시키기 위한 방법 및 약학적 조성물 |
| GB201322798D0 (en) * | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
| CA2979120A1 (en) * | 2015-03-03 | 2016-09-09 | Fondazione Telethon | Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof |
| EP3374494A4 (en) * | 2015-11-11 | 2019-05-01 | Coda Biotherapeutics, Inc. | CRISPR COMPOSITIONS AND METHODS OF USE THEREOF FOR GENE THERAPY |
-
2019
- 2019-04-05 BR BR112020020204-5A patent/BR112020020204A2/pt not_active Application Discontinuation
- 2019-04-05 WO PCT/US2019/026062 patent/WO2019195727A1/en not_active Ceased
- 2019-04-05 EA EA202092069A patent/EA202092069A1/ru unknown
- 2019-04-05 CA CA3096088A patent/CA3096088A1/en not_active Withdrawn
- 2019-04-05 MA MA052199A patent/MA52199A/fr unknown
- 2019-04-05 JP JP2021504131A patent/JP2021520232A/ja not_active Withdrawn
- 2019-04-05 EP EP19718557.2A patent/EP3775233A1/en not_active Withdrawn
- 2019-04-05 MX MX2020010477A patent/MX2020010477A/es unknown
- 2019-04-05 PE PE2020001530A patent/PE20210918A1/es unknown
- 2019-04-05 US US16/376,808 patent/US20190307900A1/en not_active Abandoned
- 2019-04-05 CN CN201980031769.0A patent/CN113056561A/zh not_active Withdrawn
- 2019-04-05 JO JOP/2020/0253A patent/JOP20200253A1/ar unknown
- 2019-04-05 KR KR1020207031540A patent/KR20210005040A/ko not_active Withdrawn
- 2019-04-05 RU RU2020132890A patent/RU2020132890A/ru unknown
- 2019-04-05 AU AU2019247864A patent/AU2019247864A1/en not_active Abandoned
- 2019-04-05 SG SG11202009759SA patent/SG11202009759SA/en unknown
- 2019-04-08 TW TW108112207A patent/TW202003052A/zh unknown
-
2020
- 2020-10-02 CL CL2020002561A patent/CL2020002561A1/es unknown
- 2020-10-04 IL IL277779A patent/IL277779A/en unknown
- 2020-10-05 PH PH12020551641A patent/PH12020551641A1/en unknown
- 2020-10-30 CO CONC2020/0013690A patent/CO2020013690A2/es unknown
-
2022
- 2022-09-15 US US17/945,344 patent/US20230149566A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3775233A1 (en) | 2021-02-17 |
| AU2019247864A1 (en) | 2020-10-22 |
| WO2019195727A1 (en) | 2019-10-10 |
| MA52199A (fr) | 2021-02-17 |
| BR112020020204A2 (pt) | 2021-01-19 |
| PE20210918A1 (es) | 2021-05-19 |
| US20190307900A1 (en) | 2019-10-10 |
| JP2021520232A (ja) | 2021-08-19 |
| IL277779A (en) | 2020-11-30 |
| PH12020551641A1 (en) | 2021-07-26 |
| US20230149566A1 (en) | 2023-05-18 |
| MX2020010477A (es) | 2021-03-02 |
| CL2020002561A1 (es) | 2021-04-23 |
| SG11202009759SA (en) | 2020-10-29 |
| CN113056561A (zh) | 2021-06-29 |
| RU2020132890A (ru) | 2022-05-06 |
| KR20210005040A (ko) | 2021-01-13 |
| TW202003052A (zh) | 2020-01-16 |
| CA3096088A1 (en) | 2019-10-10 |
| CO2020013690A2 (es) | 2021-04-19 |
| EA202092069A1 (ru) | 2021-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551641A1 (en) | Compositions and methods for treating macular dystrophy | |
| MX2022004786A (es) | Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular. | |
| EP4427808A3 (en) | Compositions and methods for reducing ocular neovascularization | |
| CY1121348T1 (el) | Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων | |
| EA201892431A1 (ru) | Олигонуклеотиды для лечения заболевания глаз | |
| PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| WO2020097511A3 (en) | Messenger rna therapy for treatment of ocular diseases | |
| WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
| EP4345165A3 (en) | Gene therapy for retinitis pigmentosa | |
| ZA201705628B (en) | Methods and compositions for treating genetic eye diseases | |
| WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
| MX2018005286A (es) | Constructo genetico. | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| MX2022013356A (es) | Avv que codifica mirna dirigido al gen htt y usos del mismo. | |
| MY186271A (en) | Ophthalmic compositions and methods of use therefor | |
| WO2019217397A3 (en) | Compositions and methods for improving strand biased | |
| PH12020551071A1 (en) | Compositions and methods for treating retinal disorders | |
| BR112017005235A2 (pt) | vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc) | |
| AU2017256910A1 (en) | Optogenetic visual restoration using Chrimson | |
| MX388737B (es) | Oligonucleótidos terapéuticos. | |
| BR112018017240A2 (pt) | ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, método para fabricar um vetor viral adenoassociado recombinante? | |
| MY209392A (en) | Use of amino acid supplementation for improved muscle protein synthesis | |
| BR112019003912A2 (pt) | composição, método para criação de um hidrogel, matriz, hidrogel, método para indução da formação ou regeneração de um tecido neuronal, método para tratamento de uma lesão do nervo e método para prevenção ou tratamento de choque neurogênico após lesão do nervo | |
| MX2019007041A (es) | Metodos y composiciones para tratar la enfermedad de parkinson. | |
| WO2016069950A3 (en) | Methods of treating hypoxia-associated optical conditions with cartilage oligo matrix protein-angiopoietin 1 (comp-ang1) |